Glucocorticoid maintenance therapy and severe infectious complications in ANCA-associated vasculitis: a retrospective analysis.

Rheumatology International
Claudius SpeerMatthias Schaier

Abstract

To study the impact of glucocorticoid maintenance dose and treatment duration on outcomes in patients with AAV (ANCA-associated vasculitis) with emphasis on infectious complications. A total of 130 AAV patients from two German vasculitis centers diagnosed between August 2004 and January 2019 treated with cyclophosphamide and glucocorticoids for induction therapy and glucocorticoids for maintenance therapy were retrospectively enrolled. We investigated the influence of glucocorticoid maintenance therapy on patient survival, time to relapse, kidney function, infectious complications and irreversible physical damage. The patients were divided into the following groups: patients treated according to the predefined reduction scheme (< 7.5 mg) or patients treated with glucocorticoids ≥ 7.5 mg after 6 months. Compared to patients receiving < 7.5 mg glucocorticoids after 6 months, patients receiving [Formula: see text] 7.5 mg had an increased rate of infectious episodes per patient (1.7 vs. 0.6; p < 0.001), including urinary tract infection (p = 0.007), pneumonia (p = 0.003), opportunistic pneumonia (p = 0.022) and sepsis (p = 0.008). Especially pneumonia during the first 24 months after disease onset [hazard ratio, 3.0 (95% CI 1.5 - 6...Continue Reading

References

Feb 1, 1994·Arthritis and Rheumatism·J C JennetteC G Kallenberg
Nov 20, 1997·The New England Journal of Medicine·J C Jennette, R J Falk
Jul 4, 2003·The New England Journal of Medicine·David JayneUNKNOWN European Vasculitis Study Group
Jun 22, 2007·Journal of the American Society of Nephrology : JASN·David R W JayneUNKNOWN European Vasculitis Study Group
Dec 5, 2008·Annals of the Rheumatic Diseases·C MukhtyarR A Luqmani
May 20, 2009·Annals of Internal Medicine·Kirsten de GrootUNKNOWN EUVAS (European Vasculitis Study Group)
Jun 11, 2009·Best Practice & Research. Clinical Rheumatology·Jennifer Turnbull, Lorraine Harper
Jul 22, 2010·The New England Journal of Medicine·Rachel B JonesUNKNOWN European Vasculitis Study Group
Jul 22, 2010·The New England Journal of Medicine·John H StoneUNKNOWN RAVE-ITN Research Group
Nov 10, 2010·JAMA : the Journal of the American Medical Association·Thomas F HiemstraUNKNOWN European Vasculitis Study Group (EUVAS)
Nov 27, 2010·Annals of the Rheumatic Diseases·Oliver FlossmannUNKNOWN European Vasculitis Study Group
Dec 3, 2011·Clinical Journal of the American Society of Nephrology : CJASN·JulieAnne G McGregorPatrick H Nachman
Aug 2, 2013·The New England Journal of Medicine·Ulrich SpecksUNKNOWN RAVE-ITN Research Group
Mar 26, 2015·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Matthias SchaierClaudia Sommerer
Apr 13, 2017·Journal of the American Society of Nephrology : JASN·David R W JayneUNKNOWN CLEAR Study Group
May 27, 2017·Annals of the Rheumatic Diseases·Alexandre KarrasUNKNOWN European Vasculitis Society
Feb 14, 2020·The New England Journal of Medicine·Michael WalshUNKNOWN PEXIVAS Investigators

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA

Software Mentioned

REMAIN
SPSS
CYCLOPS
GraphPad Prism
GraphPad
MEPEX

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.